DeepCure

Today, DC-15442, our second development candidate, is a success for patients and for our approach to drug discovery. 🎉 DeepCure was founded to design drugs for transcription factors like #STAT6, which have long been considered impossible to drug with small molecules. We knew that with a strong team of scientists, the right blend of physics-based AI tools, and an unwavering commitment to solving hard problems, breakthroughs were possible where others had failed. Huge thanks to the team for making this milestone a reality! 🙏

DeepCure does it again! Today, we announced our second development candidate, DC-15442, an oral STAT6 inhibitor delivering the full efficacy of “dupilumab-in-a-pill” - without protein degradation. DC-15442 combines outstanding efficacy with an exceptional safety profile, making it ideal for the chronic management of asthma, atopic dermatitis, and other inflammatory conditions. #Pharmaceuticals #ArtificialIntelligence #Immunology #STAT6 https://lnkd.in/e5gwJcZz

This week at Lab of the Future 2025 I had an insightful conversation with Rob Brown, Global VP at Sapio Sciences, John Chan, Head of ShinrAI Center for Artificial Intelligence and Machine Learning at Takeda and Michail V., Senior Engineer at AbbVie. We heard three great presentations highlighting how AI, with the right guardrails, can help accelerate scientific workflows and perform tedious tasks such as taking lab notes. In the panel afterwards, we discussed the evolving role of AI agents as thought partners in drug discovery. I am personally most excited by AI technologies that can go beyond automation of routine tasks and truly collaborate with scientists. At DeepCure, our scientists value the back-and-forth with AI to generate and systematically explore novel ideas. In our co-creative process, AI provided both intuition and data-driven insights, and that enabled us to achieve breakthroughs in drugging key targets for inflammation and immunology. #LOTF2025 #LaboftheFuture #Congress #AICoScientist #DeepCure #Biopharma

At DeepCure, we’re drugging tough targets 🎯 that can transform patient lives. This would not be possible without our dedicated, talented team that strive every day to solve the hardest problems in biology and chemistry and to make better medicines. 🙌 We are grateful—it's inspiring and a joy to work with every single one of you! 💖

How can scientists take advantage of AI’s creativity to discover novel, safer therapeutics for some of the toughest targets? 🧐 Thrasyvoulos Karydis, our co-founder & CTO, will be at day 4 of #DeepFest25 tomorrow, February 12, to talk about Unlocking AI’s Creativity to Rethink the Science of Drug Discovery. Join him in Hall 5 at the main stage to find out how. 👉 http://bit.ly/3QfB9YC Ready to hear more? You can also find Thras on the February 3rd episode of the LEAP:IN podcast. Listen in to learn about DeepCure's mission and tech. 🎧 https://bit.ly/40G7WuQ #DeepFest2025 #LEAP25 #IntoNewWorlds

Our CEO & Co-Founder Kfir Schreiber and our team was at #BiotechShowcase #JPM25. He spoke on the AI revolutionizing therapeutic drug development panel alongside other executives, Andrei Georgescu, Ph.D. CEO of Vivodyne, Wyatt McDonnell CEO Infinimmune, and other execs moderated by Maria Luisa Pineda, PhD. from Envisagenics. Great seeing all of you and looking forward to sharing more updates in 2025. #drugdiscovery #AI

Our CEO & Co-Founder Kfir Schreiber was recently quoted in a WSJ article: "Sorting Opportunity from Hype in Healthcare AI." Biotech company DeepCure uses AI to discover medicines that hit challenging biological targets. The Boston-based company expects to move its first medication, for advanced rheumatoid #arthritis, into clinical trials later this year, co-founder and CEO Kfir Schreiber said. Venture capitalists are looking increasingly at the output of biotech AI technologies, he said. #drugdiscovery #drugdevelopment #healthcare #AI Read the article:

AI, ML, & LLM: Revolutionizing Therapeutic Development 📍 Biotech Showcase 🌍 San Francisco, CA 📆 January 15, 2025 🕖 14:30 – 15:30 Large language models (LLMs) and artificial intelligence (AI) are transforming the pharmaceutical industry by streamlining processes across the entire drug development lifecycle. These technologies enable researchers to generate hypotheses, extract insights from vast datasets, detect patterns, and simplify literature searches through natural language interactions. Beyond drug discovery, AI has the potential to revolutionize various aspects of therapeutic development, including research, clinical trials, regulatory filings, and manufacturing. This session is open to life science professionals. Take advantage of this opportunity to explore the program and experience what Biotech Showcase has to offer. RSVP is required to reserve your spot! RSVP now >> https://lnkd.in/gHhFJN5S Moderator: Maria Luisa Pineda, PhD.   Panelists: Andrei Georgescu, Ph.D. Wyatt McDonnell Khai Minh Pham MD, PhD (AI) Kfir Schreiber Hannah Wastyk   #BiotechShowcase #SanFrancisco Sara Jane Demy

Excited to announce the discovery of potent, selective oral small molecule inhibitors of STAT6. These next-generation STAT6 inhibitors demonstrate excellent oral bioavailability, cell permeability, and metabolic stability, and do not target STAT6 for degradation. DeepCure expects to select a development candidate and enter IND-enabling studies next year. “Our STAT6 program represents a significant advancement in the discovery of an oral inhibitor for type 2 inflammatory diseases to overcome the limitations seen with marketed injectable therapies,” said Kfir Schreiber, CEO & Founder, DeepCure. “We plan to select a development candidate and advance to IND studies next year to address major unmet needs in the treatment of asthma, atopic dermatitis, COPD and other inflammatory diseases.” Read the release: https://lnkd.in/e5TuuQhN